Martin Bassett, MD
Endocrinology, Diabetes & Metabolism · Keizer, ORNPI 1437163029
Payments from drug & device makers
Across 559 payments — averaging $35.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$10K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Abbott$811
- Amgen$783
- Xeris Pharmaceuticals, Inc.$780
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$10,20052%
- Food & beverage$9,36647%
- Education$1911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 27 | $10,315 |
| Novo Nordisk | 111 | $1,351 |
| Lilly USA, LLC | 75 | $1,308 |
| Abbott | 47 | $811 |
| Amgen(2 entities) | 31 | $783 |
| Xeris Pharmaceuticals, Inc. | 33 | $780 |
| AstraZeneca(2 entities) | 37 | $701 |
| Sanofi-aventis U.S. LLC | 25 | $418 |
| Boehringer Ingelheim | 16 | $396 |
| Bayer | 27 | $378 |
| Mannkind Corporation | 19 | $321 |
| Medtronic(2 entities) | 18 | $309 |
| Amryt Pharma Holdings Ltd | 11 | $260 |
| Corcept Therapeutics | 10 | $191 |
| Recordati_rare_diseases_inc. | 7 | $163 |
| Merck | 9 | $152 |
| Astellas Pharma US Inc | 3 | $141 |
| Novartis | 6 | $139 |
| Dexcom, Inc. | 8 | $133 |
| Zealand Pharma US, Inc. | 6 | $106 |
| Radius Health, Inc. | 5 | $102 |
| Esperion Therapeutics, Inc. | 6 | $98 |
| Chiasma, Inc. | 2 | $89 |
| Lifescan, Inc. | 3 | $48 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Insulet Corporation | 2 | $40 |
| Johnson & Johnson | 4 | $37 |
| Pfizer | 2 | $35 |
| AbbVie | 2 | $31 |
| Alfasigma USA, Inc. | 2 | $29 |
| Shire North American Group Inc | 1 | $20 |
| IBSA Pharma Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$10,200
- EVENITY$125
- GVOKE HYPOPEN$107
How this compares
$19,758 in reported general payments places this provider in the 70th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
See all endocrinology, diabetes & metabolism providers in Oregon →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 339 | $398,460 |
| JardianceEmpagliflozin | 183 | $189,584 |
| TrulicityDulaglutide | 131 | $167,307 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $150,856 |
| MounjaroTirzepatide | 54 | $60,513 |
| ForteoTeriparatide | 12 | $59,779 |
| FarxigaDapagliflozin Propanediol | 65 | $58,090 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 51 | $52,473 |
| KerendiaFinerenone | 69 | $51,562 |
| Humalog Kwikpen U-200Insulin Lispro | 30 | $49,762 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $49,563 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $48,983 |
| RybelsusSemaglutide | 31 | $44,019 |
| Teriparatide | 20 | $42,268 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $40,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,351 | $452,109404 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $1,308 | $302,179238 claims |
| Boehringer IngelheimJardiance, Tradjenta | $396 | $213,668211 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $418 | $60,13180 claims |
| AstraZenecaFarxiga | $701 | $58,09065 claims |
| BayerKerendia | $378 | $51,56269 claims |
| Radius Health, Inc.Tymlos | $102 | $37,23113 claims |
| Johnson & JohnsonInvokana | $37 | $20,21813 claims |
| MerckJanuvia | $152 | $18,55833 claims |
| AmgenProlia | $783 | $18,41711 claims |
| AbbVieSynthroid | $31 | $6,20788 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 76 endocrinology, diabetes & metabolism providers in Oregon.
Other endocrinology, diabetes & metabolism in Keizer
- Rodica BusuiPortland$2.6M
- Michael McClungPortland$1.3M
- Jonathan PurnellPortland$1.1M
- Patricia HopsonCorvallis$1.1M
- Maria FleseriuPortland$980K
- Andrew AhmannPortland$575K
- Paul DuellPortland$463K
- James NeifingPortland$311K
- Joseph El YoussefCoos Bay$242K
- Eric OrwollPortland$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.